Logo image of UPH

UPHEALTH INC (UPH) Stock Fundamental Analysis

USA - NYSE:UPH - US91532B2007 - Common Stock

0.3 USD
+0.03 (+9.13%)
Last: 12/11/2023, 8:20:46 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to UPH. UPH was compared to 35 industry peers in the Health Care Technology industry. UPH may be in some trouble as it scores bad on both profitability and health. UPH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

UPH had negative earnings in the past year.
In the past year UPH has reported a negative cash flow from operations.
UPH Yearly Net Income VS EBIT VS OCF VS FCFUPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -100M -200M -300M

1.2 Ratios

UPH has a Return On Assets (-31.98%) which is comparable to the rest of the industry.
UPH's Return On Equity of -117.29% is on the low side compared to the rest of the industry. UPH is outperformed by 62.79% of its industry peers.
UPH has a Return On Invested Capital of 1.59%. This is amongst the best in the industry. UPH outperforms 86.05% of its industry peers.
Industry RankSector Rank
ROA -31.98%
ROE -117.29%
ROIC 1.59%
ROA(3y)-42.12%
ROA(5y)N/A
ROE(3y)-106.75%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UPH Yearly ROA, ROE, ROICUPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

The Operating Margin of UPH (0.90%) is better than 81.40% of its industry peers.
The Gross Margin of UPH (45.52%) is worse than 60.47% of its industry peers.
Industry RankSector Rank
OM 0.9%
PM (TTM) N/A
GM 45.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UPH Yearly Profit, Operating, Gross MarginsUPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -100 -200

More info and screens

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), UPH is destroying value.
Compared to 1 year ago, UPH has more shares outstanding
Compared to 1 year ago, UPH has a worse debt to assets ratio.
UPH Yearly Shares OutstandingUPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 5M 10M 15M 20M
UPH Yearly Total Debt VS Total AssetsUPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -3.70, we must say that UPH is in the distress zone and has some risk of bankruptcy.
UPH's Altman-Z score of -3.70 is on the low side compared to the rest of the industry. UPH is outperformed by 67.44% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that UPH is not too dependend on debt financing.
UPH has a better Debt to Equity ratio (0.03) than 69.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -3.7
ROIC/WACC0.24
WACC6.53%
UPH Yearly LT Debt VS Equity VS FCFUPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 100M 200M 300M

2.3 Liquidity

UPH has a Current Ratio of 0.13. This is a bad value and indicates that UPH is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.13, UPH is doing worse than 97.67% of the companies in the same industry.
A Quick Ratio of 0.13 indicates that UPH may have some problems paying its short term obligations.
With a Quick ratio value of 0.13, UPH is not doing good in the industry: 97.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
UPH Yearly Current Assets VS Current LiabilitesUPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.97% over the past year.
Looking at the last year, UPH shows a small growth in Revenue. The Revenue has grown by 3.24% in the last year.
EPS 1Y (TTM)34.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.46%
Revenue 1Y (TTM)3.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-15.49%

3.2 Future

UPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.89% yearly.
Based on estimates for the next years, UPH will show a decrease in Revenue. The Revenue will decrease by -0.68% on average per year.
EPS Next Y72.87%
EPS Next 2Y40.69%
EPS Next 3Y23.89%
EPS Next 5YN/A
Revenue Next Year-7.87%
Revenue Next 2Y-37.26%
Revenue Next 3Y-0.68%
Revenue Next 5YN/A

3.3 Evolution

UPH Yearly Revenue VS EstimatesUPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 50M 100M 150M
UPH Yearly EPS VS EstimatesUPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UPH Price Earnings VS Forward Price EarningsUPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, UPH is valued cheaper than 90.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.37
UPH Per share dataUPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as UPH's earnings are expected to grow with 23.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.69%
EPS Next 3Y23.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UPHEALTH INC

NYSE:UPH (12/11/2023, 8:20:46 PM)

0.3

+0.03 (+9.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-20 2023-11-20/amc
Earnings (Next)02-29 2024-02-29/amc
Inst Owners0.11%
Inst Owner Change0%
Ins Owners112.9%
Ins Owner Change0%
Market Cap5.33M
Analysts82.5
Price Target5.24 (1646.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-362.92%
Min EPS beat(2)-624.95%
Max EPS beat(2)-100.89%
EPS beat(4)1
Avg EPS beat(4)-206.44%
Min EPS beat(4)-624.95%
Max EPS beat(4)19.85%
EPS beat(8)3
Avg EPS beat(8)-213.41%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.44%
Min Revenue beat(2)13.83%
Max Revenue beat(2)15.05%
Revenue beat(4)4
Avg Revenue beat(4)11.19%
Min Revenue beat(4)0.81%
Max Revenue beat(4)15.06%
Revenue beat(8)4
Avg Revenue beat(8)2%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.55%
PT rev (3m)-14.55%
EPS NQ rev (1m)43.5%
EPS NQ rev (3m)43.5%
EPS NY rev (1m)-11.26%
EPS NY rev (3m)-11.26%
Revenue NQ rev (1m)12.58%
Revenue NQ rev (3m)112482%
Revenue NY rev (1m)5.99%
Revenue NY rev (3m)5.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.08
P/tB N/A
EV/EBITDA 10.37
EPS(TTM)-7.7
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-1.59
FCFYN/A
OCF(TTM)-1.31
OCFYN/A
SpS8.61
BVpS3.61
TBVpS-2.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.98%
ROE -117.29%
ROCE 2.01%
ROIC 1.59%
ROICexc 1.67%
ROICexgc N/A
OM 0.9%
PM (TTM) N/A
GM 45.52%
FCFM N/A
ROA(3y)-42.12%
ROA(5y)N/A
ROE(3y)-106.75%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.12
Cap/Depr 37.34%
Cap/Sales 3.21%
Interest Coverage 0.09
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z -3.7
F-Score5
WACC6.53%
ROIC/WACC0.24
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.46%
EPS Next Y72.87%
EPS Next 2Y40.69%
EPS Next 3Y23.89%
EPS Next 5YN/A
Revenue 1Y (TTM)3.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-15.49%
Revenue Next Year-7.87%
Revenue Next 2Y-37.26%
Revenue Next 3Y-0.68%
Revenue Next 5YN/A
EBIT growth 1Y102.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year214.28%
EBIT Next 3Y43.77%
EBIT Next 5YN/A
FCF growth 1Y45.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.9%
OCF growth 3YN/A
OCF growth 5YN/A